Jeffrey William  Henderson net worth and biography

Jeffrey Henderson Biography and Net Worth

Jeffrey W. Henderson serves as a director of BD (Becton, Dickinson and Company), a global medical technology company headquartered in Franklin Lakes, New Jersey. Henderson has been a member of the board since 2018.

Henderson is the president of JWH Consulting LLC, a business and investment advisory firm, focused primarily on the healthcare industry. He previously served as an advisory director to Berkshire Partners LLC, a private equity firm, from September 2015 to December 2019. Henderson served as chief financial officer of Cardinal Health Inc., a global healthcare products and services company, from May 2005 to November 2014. Prior to joining Cardinal Health, Henderson held multiple positions at Eli Lilly and General Motors, including international positions. He serves as a director of Qualcomm, Inc. and Halozyme Therapeutics, Inc. Henderson previously served on the board of FibroGen, Inc.

Henderson is an experienced healthcare executive who brings to the Board a deep knowledge of the industry, along with strong financial, strategic and operational expertise and significant international experience. He brings valuable corporate governance experience from his service as a director of other public companies.

What is Jeffrey William Henderson's net worth?

The estimated net worth of Jeffrey William Henderson is at least $7.66 million as of March 3rd, 2025. Mr. Henderson owns 33,611 shares of Becton, Dickinson and Company stock worth more than $7,661,964 as of March 25th. This net worth approximation does not reflect any other assets that Mr. Henderson may own. Learn More about Jeffrey William Henderson's net worth.

How do I contact Jeffrey William Henderson?

The corporate mailing address for Mr. Henderson and other Becton, Dickinson and Company executives is 1 BECTON DRIVE, FRANKLIN LAKES NJ, 07417. Becton, Dickinson and Company can also be reached via phone at (201) 847-6800 and via email at investor.relations@bd.com. Learn More on Jeffrey William Henderson's contact information.

Has Jeffrey William Henderson been buying or selling shares of Becton, Dickinson and Company?

During the past quarter, Jeffrey William Henderson has bought $350,430.00 in Becton, Dickinson and Company stock. Most recently, on Monday, February 10th, Jeffrey William Henderson bought 1,500 shares of Becton, Dickinson and Company stock. The stock was acquired at an average cost of $233.62 per share, with a total value of $350,430.00. Following the completion of the transaction, the director now directly owns 8,015 shares of the company's stock, valued at $1,872,464.30. Learn More on Jeffrey William Henderson's trading history.

Who are Becton, Dickinson and Company's active insiders?

Becton, Dickinson and Company's insider roster includes Richard Byrd (EVP and President, Interventional Segment ), Richard Byrd (EVP), Simon Campion (EVP), Alexandre Conroy (EVP), Christopher DelOrefice (Exec. VP & CFO ), Claire Fraser (Director), John Gallagher (VP), Michael Garrison (EVP), Roland Goette (EVP), Jeffrey Henderson (Director), David Hickey (EVP), Patrick Kaltenbach (EVP), Samrat Khichi (EVP), Betty Larson (EVP), James Lim (EVP), Shana Neal (EVP and Chief People Officer), Thomas Polen, Jr. (Insider), Rebecca Rimel (Director), Bertram Scott (Director), and Thomas Spoerel (VP). Learn More on Becton, Dickinson and Company's active insiders.

Are insiders buying or selling shares of Becton, Dickinson and Company?

During the last year, Becton, Dickinson and Company insiders bought shares 1 times. They purchased a total of 1,500 shares worth more than $350,430.00. During the last year, insiders at the medical instruments supplier sold shares 13 times. They sold a total of 21,558 shares worth more than $4,945,585.53. The most recent insider tranaction occured on March, 18th when EVP Richard Byrd sold 459 shares worth more than $105,570.00. Insiders at Becton, Dickinson and Company own 0.4% of the company. Learn More about insider trades at Becton, Dickinson and Company.

Information on this page was last updated on 3/18/2025.

Jeffrey William Henderson Insider Trading History at Becton, Dickinson and Company

See Full Table

Jeffrey William Henderson Buying and Selling Activity at Becton, Dickinson and Company

This chart shows Jeffrey William Henderson's buying and selling at Becton, Dickinson and Company by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$350kbought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$200k$0$200kTotal Insider BuyingTotal Insider Selling

Becton, Dickinson and Company Company Overview

Becton, Dickinson and Company logo
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
Read More

Today's Range

Now: $227.96
Low: $226.48
High: $231.82

50 Day Range

MA: $232.27
Low: $222.65
High: $249.75

2 Week Range

Now: $227.96
Low: $218.75
High: $251.99

Volume

1,675,001 shs

Average Volume

1,533,934 shs

Market Capitalization

$65.46 billion

P/E Ratio

37.87

Dividend Yield

1.79%

Beta

0.35